At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses.
Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers.
In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations.
We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s.
We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.
-
Industry
-
Biotechnology Research
-
Company size
-
2-10 employees
-
Headquarters
-
Malvern, Pennsylvania
-
Type
-
Privately Held
-
Founded
-
2008
-
Specialties
-
Neurodegeneration, Alzheimer’s, Parkinson’s, Alzheimer’s in Down Syndrome, Axonal Transport, Traumatic Brain Injury, APP, tau, aSYN, neurotoxic proteins, APP/Ab (APP), tau/phospho-tau, and a-Synuclein (a-SYN)
